|
Neonatal Intensive Care Drug Manual
|
| bet | 145/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Dexamethasone
Revision Date : April 2020
|
Approved : TC, KOH
|
Alert
|
Dexamethasone is available as Dexamethasone phosphate or dexamethasone sodium phosphate.
The conversion factor for dexamethasone:
1 mg dexamethasone base = 1.2 mg dexamethasone phosphate =
1.3 mg dexamethasone sodium phosphate
There is a non TGA registered commercial product, Dexsol®oral syrup. However, a SAS form is required for supply.
|
Indication
|
To facilitate weaning from assisted ventilation and improve lung function in infants at risk of chronic lung disease.
To facilitate extubation.
|
Action
|
Long acting glucocorticoid with potent anti-inflammatory action.
No significant mineralocorticoid activity.
|
Drug type
|
Adrenal steroid hormone.
|
Trade name
|
IV: (1) dexamethasone phosphate Mylan, (2) DBL dexamethasone phosphate Hospira, (3) dexamethasone phosphate Alphapharm, (4) DBL Dexamethasone sodium phosphate Pfizer
Oral: Compounded by pharmacy in-house. Refer to special comments section.
There is a non TGA registered commercial product, Dexsol®oral syrup. However, a SAS form is required for supply.
|
Presentation
|
IV preparations:
All 4 IV preparations: 1 mL contains 3.4 mg of dexamethasone base equivalent to 4.4 mg of dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate
Oral: 0.05mg/mL, 0.1mg/mL, 0.5 mg/mL or 1 mg/mL solution or suspension – Prepared by pharmacy in-house. Refer to special comments section for further information.
|
Dose
|
|
|
| |
